ArticleResearch square2024

Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for Neuroblastoma.

Li Che-Hsing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.